Group 1: Medical Device Sector - The medical device sector is expected to see valuation recovery opportunities due to "policy optimization, economic recovery, and performance rebound" [1] - Since 2025, medical device bidding has been gradually improving, with some companies likely to see performance reversals in Q3 2025 as inventory is consumed [1] - High-value consumables have faced performance and valuation suppression due to centralized procurement and tariffs, but the easing of these factors presents significant valuation recovery opportunities [1] Group 2: Innovative Drugs - Multiple results of domestic innovative drugs will be showcased at the European Society for Medical Oncology (ESMO) in mid to late October 2025, highlighting the competitive clinical data of Chinese innovative drugs [2] - The trend of domestic innovative drugs going overseas is strengthening, with significant clinical progress and data readouts enhancing their global market commercialization certainty [3] - The Chinese innovative drug industry is showing a long-term positive development trend, particularly evident in the explosive growth of business development (BD) transactions in recent years [3]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry in China [5]. Core Insights - The ESMO conference showcased significant breakthroughs in both foreign and domestic innovative drugs, highlighting the competitive strength of Chinese pharmaceutical companies on the international stage [3][12]. - The report emphasizes the potential of domestic innovative drugs to redefine standard therapies, particularly in the context of PD-1/VEGF dual antibodies and antibody-drug conjugates (ADCs) [8][29]. Summary by Sections 1. PD-1 plus and Domestic Dual Antibodies - The PD-(L)1/VEGF dual antibody, Ivosidenib, demonstrated strong positive results in a Phase III trial for first-line treatment of advanced squamous non-small cell lung cancer (NSCLC), showing a progression-free survival (PFS) improvement of 4.2 months compared to the PD-1 group [13][16]. - SSGJ-707, a PD-1/VEGF dual antibody, showed promising results in treating microsatellite stable (MSS) colorectal cancer, with an overall response rate (ORR) of 68.7% and a disease control rate (DCR) of 98.5% [18][19]. - HB0025, another PD-L1/VEGF dual antibody, reported an ORR of 83.3% in squamous NSCLC patients, indicating strong anti-tumor efficacy [20][21]. 2. ADCs: Accelerated Breakthroughs - SKB264, an ADC, has shown significant PFS and overall survival (OS) benefits in a Phase III trial for EGFR-mutant NSCLC, with PFS HR of 0.49 and OS HR of 0.60, indicating its potential as a new standard therapy [29][30]. - In the breast cancer domain, SKB264 demonstrated an ORR of 41.5% in CDK4/6i pre-treated HR+/HER2- advanced breast cancer, significantly outperforming chemotherapy [31][32]. - The report highlights the global potential of SKB264, with ongoing studies expected to further validate its efficacy and safety profile [23][29].

Core Viewpoint - The main stock index in South Africa increased by 1% to reach 109,926 points on October 23 [1] Group 1 - The rise in the stock index indicates positive market sentiment in South Africa [1]

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report emphasizes the significance of the ESMO conference, highlighting the achievements of Chinese pharmaceutical companies and suggesting to focus on catalysts such as policies, academic conferences, and business development in Q4 2025 [1][4] - The report indicates a potential market rebound due to increasing industry catalysts, including various academic conferences and favorable policies [4] - The report recommends continued attention to companies with promising clinical pipelines and their global commercialization potential [4][5] Valuation Summary - The report provides a detailed valuation overview of various companies, with all covered companies rated as "Buy" except for two rated as "Neutral" and one as "Sell" [3] - Notable target prices and current prices for selected companies include: - AstraZeneca: Target price 93.30, Current price 83.87 [3] - BeiGene: Target price 225.00, Current price 188.20 [3] - Innovent Biologics: Target price 48.00, Current price 36.42 [3] - I-Mab: Target price 105.00, Current price 86.10 [3] - China Biologic Products: Target price 9.10, Current price 7.43 [3] Market Performance - The Hang Seng Index rose by 2.3% and the Hang Seng Healthcare Index increased by 2.0% during the week of October 14-21, 2025, ranking fifth among twelve industry indices [4][7] - Sub-industry performance showed CXO leading with a 4.5% increase, followed by Internet medicine and biopharmaceuticals [4][7] Institutional Holdings - As of October 21, 2025, the proportion of domestic institutional holdings through Hong Kong Stock Connect decreased slightly to 22.1%, while foreign institutional holdings also saw a minor decline to 38.6% [34][38] - The report notes that both domestic and foreign investors are increasing their positions in innovative drug companies with clear pipeline values [4][38] Clinical Developments - The report highlights significant clinical trial results presented at the ESMO conference, including: - CanSino Biologics' promising data on its PD-1/VEGF inhibitor [5][6] - Rongchang Biopharmaceuticals' HER2 ADC showing significant survival benefits [5][6] - Kelun-Biotech's results indicating substantial improvements in progression-free survival [5][6] - The report suggests that these developments enhance the global competitiveness of the covered companies [5][6]

Group 1 - Multiple domestic pharmaceutical companies, including Innovent Biologics and Hengrui Medicine, announced business development (BD) deals within two days, indicating a trend of increased collaboration in the industry [1] - Innovent Biologics entered a global strategic partnership with Takeda Pharmaceutical, receiving an upfront payment of $1.2 billion, including a $100 million strategic equity investment, with potential milestone payments up to $10.2 billion [1] - Despite these positive developments, the Hong Kong innovation drug index fell over 1%, with a decline of more than 15% since October 8, contrasting sharply with previous market reactions to BD announcements [1] Group 2 - Analysts suggest that liquidity issues and valuation pressures from previous gains are causing a slowdown in the innovation drug sector, with the market showing less enthusiasm for BD transaction amounts [2][3] - The total amount of external licensing for Chinese innovative drugs surpassed $100 billion for the year, marking a historical milestone [2] - The sentiment in the pharmaceutical sector has returned to a more comfortable trading range, awaiting capital inflows [3] Group 3 - The focus remains on the international competitiveness of domestic innovative drugs and the trend of BD transactions abroad [5] - The U.S. pharmaceutical market has experienced volatility due to various pressures from the Trump administration, including threats of high tariffs on drugs [6] - Despite these pressures, the potential negative impacts on the industry are expected to be limited, with the narrative logic of BD transactions remaining intact [7] Group 4 - The upcoming quarterly reports are anticipated to show performance improvements, alongside the continued rollout of BD transactions [4] - The sentiment in the A-share pharmaceutical and biotechnology sector has dropped below the historical median, indicating a potential for recovery as market conditions stabilize [8]

Market Performance - The Hang Seng Healthcare Index decreased by 2.71% as of October 23, 2025, with mixed performance among constituent stocks [2] - The Hang Seng Medical ETF (513060) fell by 2.41%, with a latest price of 0.65 CNY, but has seen a 3.42% increase over the past three months [2] - The Hong Kong Stock Connect Innovative Drug Selection Index dropped by 3.70%, with the Hong Kong Innovative Drug Selection ETF (520690) down by 3.26% [4][5] - The CSI Pharmaceutical 50 Index declined by 0.95%, while the Pharmaceutical 50 ETF (159838) decreased by 0.96% [6] Liquidity and Trading Activity - The Hang Seng Medical ETF had a turnover of 11.25% and a trading volume of 763 million CNY, indicating active market participation [2] - The Hong Kong Innovative Drug Selection ETF recorded a turnover of 21.44% with a trading volume of approximately 98.5 million CNY [5] - The Pharmaceutical 50 ETF had a turnover of 1.67% and a trading volume of 2.71 million CNY [6] Key Events and Trends - The flu season has started early, leading to a rise in flu-related stocks, with companies like Hendi Pharmaceutical and Duori Pharmaceutical seeing significant gains [7] - The ongoing ESMO (European Society for Medical Oncology) conference has heightened interest in Chinese pharmaceutical companies, showcasing clinical data from firms like Heng Rui Pharmaceutical and Ke Long Bo Tai [7] - The collaboration between Sinopharm and Takeda is expected to enhance foreign investment confidence in Chinese innovative drug assets [7] Industry Insights - The Chinese innovative drug sector is accelerating its international presence, with 135 licensing-out transactions recorded from January to October 17, 2025, totaling over 102.9 billion USD [7] - The ESMO conference highlighted 23 LBA studies led by Chinese scholars, demonstrating the global competitiveness of China's innovative drug pipeline [7] - The aging population is increasing the demand for chronic disease treatments, while the optimization of the medical insurance payment system and AI technology applications are injecting new vitality into the industry [8] ETF Overview - The Hang Seng Medical ETF has a current scale of 6.865 billion CNY, ranking in the top third among comparable funds [8] - The Hong Kong Innovative Drug Selection ETF reached a new high with a scale of 468 million CNY [10] - The Pharmaceutical 50 ETF tracks the top 50 pharmaceutical companies in China, with the top ten stocks accounting for 59.46% of the index [11]

Group 1 - The market continues to show a trend of dividend gains while technology stocks are experiencing a contraction, with the Hang Seng Technology Index down over 11% since October 3 [1] - The Hong Kong Central Enterprise Dividend Index has increased by over 4% during the same period, outperforming the broader market [1] - The current volatile market conditions may persist ahead of significant events such as the 15th Five-Year Plan meeting, the Federal Reserve's interest rate decision, and the deadline for "reciprocal tariffs" on November 11 [1] Group 2 - A "barbell strategy" combining dividend and technology investments is suggested as a suitable allocation choice for the near future, reflecting recent capital flows [1] - The Hong Kong Central Enterprise Dividend ETF has seen a net inflow of 310 million yuan this month, with a gain of over 4% [1] - The Hang Seng Technology Index's recent pullback enhances its allocation value, with over 300 million yuan flowing into the Hong Kong Technology ETF in October, totaling over 700 million yuan in net inflows over the last 20 trading days [1] Group 3 - Institutional consensus indicates that under a low interest rate environment, high dividends, and sustained long-term capital inflows, dividend equity assets remain attractive [1] - For Hong Kong technology stocks, increased AI capital expenditure by major players and the potential for Federal Reserve rate cuts are expected to support resilience in the medium to long term [1] - The macro liquidity and fundamental logic are anticipated to play a significant role in the fourth quarter [1] Group 4 - The barbell strategy products include the Hong Kong Central Enterprise Dividend ETF (513910), which has a slight decline of 0.06% and includes major stocks like COSCO Shipping, Orient Overseas International, and China National Offshore Oil [1] - The Hong Kong Technology ETF (159101) has a decline of 0.87% and includes over 60% of the seven major technology giants such as Alibaba and Tencent, with a special focus on innovative pharmaceuticals [2]

Core Viewpoint - The Hong Kong stock market's innovative drug sector is experiencing a decline, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping over 3.5% as of the report, indicating a potential buying opportunity for investors despite the downturn [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a trading volume exceeding 200 million yuan, continuing to exhibit high premiums in the market [1] - The innovative drug sector faced a significant drop recently, with the ETF attracting over 75 million yuan in a single day, totaling over 120 million yuan in the last four days [1] Group 2: Recent Developments - The ESMO 2025 conference recently showcased positive data for several core projects of Chinese innovative drugs [1] - On October 22, Innovent Biologics announced a global strategic partnership with Takeda Pharmaceutical worth 11.4 billion USD, setting a record for the value of business development (BD) transactions in China's innovative drug sector, involving three product rights and pipeline development [1] Group 3: Future Outlook - Huafu Securities suggests that the recent adjustments in the Hong Kong innovative drug sector may present a significant opportunity for investment in late October [1] - The long-term outlook remains positive for companies with commercialization capabilities and rich pipelines, particularly in BioPharma, potential BD targets, and cutting-edge technology [1] - The innovative drug industry is expected to benefit from interest rate cuts, with performance anticipated to improve, and the end-of-year BD period may act as a catalyst for growth [1] Group 4: Index Composition - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its linked fund (025220) passively track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which includes top ten weighted stocks such as BeiGene, China Biologic Products, Innovent Biologics, and others [1]

Core Insights - The report maintains a positive long-term outlook on innovative drugs and suggests focusing on companies showing signs of bottom reversal in the pharmaceutical and biotechnology sector [1][4]. Investment Strategy - The investment strategy emphasizes the long-term logic of innovative drugs and recommends monitoring companies with high-quality innovation capabilities, such as Kelun-Biotech, Kangfang Biologics, Innovent Biologics, and others [4]. - The report suggests a diversified investment portfolio for October 2025, including both A-shares and H-shares, with specific companies highlighted for their growth potential [4][5]. Clinical Progress and Market Trends - The report notes significant clinical data presentations at the ESMO conference, showcasing the competitive edge of domestic innovative drugs in global markets [4]. - It highlights the increasing trend of Chinese innovative drugs entering overseas markets, with a focus on the importance of global clinical data for commercialization certainty [4]. Medical Device Sector - The medical device sector is expected to experience valuation recovery due to policy optimization, improved market conditions, and performance recovery, with specific companies recommended for investment [4]. - The report indicates a rebound in medical device tenders and a potential reversal in performance for certain companies in Q3 2025 [4]. Macro Data and Industry Performance - The pharmaceutical manufacturing industry reported a cumulative revenue of 15,833.10 billion yuan with a year-on-year decline of 2.0% for the first eight months of 2025 [9]. - The overall performance of the pharmaceutical sector in September 2025 showed a decline of 1.71%, underperforming the CSI 300 index by 4.91% [10]. Company Valuation Overview - The report provides a detailed valuation overview of selected companies, indicating their market capitalization, projected net profits, and various financial ratios such as PE and ROE for 2024 to 2027 [5]. - Companies like Mindray Medical, WuXi AppTec, and Aier Eye Hospital are highlighted for their favorable investment ratings and growth prospects [5].

Group 1 - The Hong Kong Stock Connect innovative drug sector experienced a decline, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping over 3% and trading volume exceeding 1 billion yuan [1] - The ETF attracted over 75 million yuan in a single day, totaling more than 1.23 billion yuan in inflows over the past four days [1] - The recent ESMO 2025 conference revealed positive data for several core projects of Chinese innovative drugs, and a record-breaking global strategic cooperation deal worth 11.4 billion USD was announced between Innovent Biologics and Takeda Pharmaceutical [2][3] Group 2 - The top ten weighted stocks in the Hong Kong Stock Connect Innovative Drug ETF include companies like BeiGene, China Biologic Products, and Innovent Biologics, with significant market capitalizations [3] - The innovative drug sector is expected to benefit from interest rate cuts, with a positive outlook for performance and a busy period for business development (BD) deals towards the end of the year [3] - Among the 37 constituent stocks, only one, CSPC Pharmaceutical Group, saw a slight increase, while others like Rongchang Biopharmaceutical and Kelun-Bio experienced significant declines [5]